A Look At Corcept Therapeutics (CORT) Valuation After The FDA Complete Response Letter On Relacorilant

Simply Wall St.

01/13

AdvertisementWhat triggered the latest move in Corcept Therapeutics (CORT)? The recent swing in Corcept Therapeutics (CORT) shares traces back to an FDA Complete Response Letter on relacorilant for ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2603575794"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603575794\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603575794?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-01-13 07:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603575794","market":"us","top_or_hot":-1,"title":"A Look At Corcept Therapeutics (CORT) Valuation After The FDA Complete Response Letter On Relacorilant","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat triggered the latest move in Corcept Therapeutics (CORT)? The recent swing in Corcept Therapeutics (CORT) shares traces back to an FDA Complete Response Letter on relacorilant for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/a-look-at-corcept-therapeutics-cort-valuation-after-the-fda\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Corcept Therapeutics (CORT) Valuation After The FDA Complete Response Letter On Relacorilant</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Corcept Therapeutics (CORT) Valuation After The FDA Complete Response Letter On Relacorilant\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-01-13 07:22</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>AdvertisementWhat triggered the latest move in Corcept Therapeutics (CORT)? The recent swing in Corcept Therapeutics (CORT) shares traces back to an FDA Complete Response Letter on relacorilant for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/a-look-at-corcept-therapeutics-cort-valuation-after-the-fda\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/a-look-at-corcept-therapeutics-cort-valuation-after-the-fda\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1559883803.SGD","symbol_name":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/a-look-at-corcept-therapeutics-cort-valuation-after-the-fda","article_id":"2603575794","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/a-look-at-corcept-therapeutics-cort-valuation-after-the-fda","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603575794","pubTimestamp":1768260122,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What triggered the latest move in Corcept Therapeutics (CORT)?\nThe recent swing in Corcept Therapeutics (CORT) shares traces back to an FDA Complete Response Letter on relacorilant for hypertension secondary to hypercortisolism, which flagged the need for more effectiveness evidence despite pivotal trial endpoints being met.\nSee our latest analysis for Corcept Therapeutics.\nAfter the FDA setback, Corcept Therapeutics’ 1 day share price return of 2.66% and 7 day return of 7.30% have only...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","BK4007":"制药","CORT":"Corcept医疗","LU0566484027.USD":"安本美国小盘成长股","BK4532":"文艺复兴科技持仓"},"translate_title":"FDA完成Relacorilant回复函后Corcept Therapeutics(CORT)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1.5},"content_text":"AdvertisementWhat triggered the latest move in Corcept Therapeutics (CORT)? The recent swing in Corcept Therapeutics (CORT) shares traces back to an FDA Complete Response Letter on relacorilant for hypertension secondary to hypercortisolism, which flagged the need for more effectiveness evidence despite pivotal trial endpoints being met. See our latest analysis for Corcept Therapeutics. After the FDA setback, Corcept Therapeutics’ 1 day share price return of 2.66% and 7 day return of 7.30% have only partly offset a 30 day share price decline of 57.38%. The 1 year total shareholder return of 26.56% and 5 year total shareholder return of 33.26% sit against a much stronger 3 year total shareholder return of 67.11%. This suggests earlier momentum has faded and sentiment is being recalibrated around regulatory and legal uncertainties. If developments at Corcept have you reassessing biotech risk, this could be a useful moment to scan other healthcare stocks that might better match your preferred balance of growth potential and regulatory exposure. After a sharp 30 day decline, but solid multi year returns and reported annual revenue and net income growth, Corcept now trades at a steep discount to analyst targets. Is this a reset entry point, or is the market already discounting future growth? Most Popular Narrative: 58.8% Undervalued With Corcept Therapeutics last closing at US$37.50 against a narrative fair value of US$91.00, the gap is wide and very specific assumptions matter. The publication of the CATALYST study and the resulting increased awareness and screening for hypercortisolism among physicians are expanding the potential addressable patient pool, which is expected to drive significant acceleration in revenue growth over the next several years. Read the complete narrative. Want to see what kind of revenue curve and margin profile underpin that fair value? The narrative leans on compounding earnings power and a richer P/E in the outer years. Curious how those pieces fit together and what has to go right across the endocrine and oncology franchises for US$91 to stack up? Result: Fair Value of $91 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story can quickly change if relacorilant stumbles in the ongoing FDA reviews or if Korlym faces faster erosion from litigation and pricing pressure. Find out about the key risks to this Corcept Therapeutics narrative. Another View: What Do Current Market Ratios Say? While the narrative fair value sits at US$91, the current P/E of 37.7x paints a different picture. That level is higher than the US Pharmaceuticals industry at 19.6x and above peers at 34.7x, yet still below a fair ratio of 41.2x that the market could move towards. For you, that mix of premium pricing and headroom probably raises a simple question: is this closer to a stretched bet or a potential catch up story if forecasts hold? See what the numbers say about this price — find out in our valuation breakdown. NasdaqCM:CORT P/E Ratio as at Jan 2026 Build Your Own Corcept Therapeutics Narrative If you look at this and feel your own view is taking shape, you can test it against the numbers and build a custom thesis in minutes with Do it your way A great starting point for your Corcept Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision. Ready for more investment ideas? If Corcept has sharpened your thinking, do not stop here. Your next strong idea might be sitting in plain sight if you scan a few focused screens.  Spot potential mispricings by zeroing in on these 883 undervalued stocks based on cash flows that align with your preferred balance of quality and price. Ride major tech shifts by screening these 26 AI penny stocks that tie artificial intelligence themes to real business models and financials. Target income-focused opportunities by filtering for these 12 dividend stocks with yields > 3% that may fit a yield driven approach to portfolio building.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}